Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.48 |
| ▸ | RAF1 | P04049 | 10/20 | 0.43 |
| ▸ | BRAF | P15056 | 9/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30599038 | 1.00 | MTOR (0.48) | MTORPIK3CARAF1BRAFPIK3CG | |
| SCHEMBL4931004 | 0.89 | PIK3CA (0.52) | MTORPIK3CAPIK3CGPIK3R1PIK3CD | |
| SCHEMBL30599041 | 0.89 | PIK3CA (0.52) | MTORPIK3CAPIK3CGPIK3R1PIK3CD | |
| SCHEMBL4603511 | 0.89 | PIK3CA (0.52) | MTORPIK3CAPIK3CGPIK3R1PIK3CD | |
| SCHEMBL4937769 | 0.84 | MTOR (0.45) | MTORPIK3CARAF1BRAFPIK3CG | |
| SCHEMBL5182201 | 0.82 | PIK3CA (0.51) | MTORPIK3CARAF1BRAFPIK3CG | |
| SCHEMBL4934405 | 0.79 | PIK3CA (0.58) | MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL5593037 | 0.79 | PIK3CA (0.66) | MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL4937600 | 0.78 | JAK3 (0.53) | MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL4603008 | 0.77 | PIK3CA (0.53) | MTORPIK3CAPIK3CGPIK3R1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| WO-2023168298-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-09-07 | — | — | WO | claimed |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023168298-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PASS MARTIN | 2008-02-28 | — | — | US | disclosed |
| EP-1778681-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006005918-A1 | 2, 4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | MTOR 196/4885PIK3CA 1307/4885RAF1 286/4885 |
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | MTOR 288/4885PIK3CA 1/4885RAF1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.